Jeffs brings over 25 years of biopharmaceutical industry experience, including 18 years at United Therapeutics where he retired in 2016 as president and co-CEO.
At United Therapeutics, Jeffs led the clinical development, regulatory approval, and commercialization of six rare disease products and managed the commercial effort that produced USD1.5 bn in annual revenue.
Prior to United Therapeutics, he held positions in clinical development at Amgen and Burroughs Wellcome.
Jeffs currently serves as a member of the board of directors of 4 public biopharma companies: Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals, and Sangamo Therapeutics.
Spyryx Biosciences is developing innovative therapeutics to address severe pulmonary diseases. Its lead clinical candidate, SPX-101, is completing a multinational Phase 2 study as a novel treatment for cystic fibrosis.
The company is funded by a first-tier syndicate of life science investors, including Canaan Partners, 5AM Ventures, and Hatteras Venture Partners.
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
SalioGen Therapeutics names new chief medical officer
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis